2011emaApproval — Fidaxomicin· Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg. Consideration should be given to official guidelines on the appropriate use of antibacterial agents. Dificlir granules for oral suspension is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age. Consideration should be given to official guidelines on the appropriate use of antibacterial agents. source ↗

2006emaApproval — Growth Hormone· Infants, children and adolescents Growth disturbance due to insufficient secretion of growth hormone (GH). Growth disturbance associated with Turner syndrome. Growth disturbance associated with chronic renal insufficiency. Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later. Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing. Adults Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Association of preterm birth and birth size status with neurodevelopmental and psychiatric disorders in spontaneous births.

European child & adolescent psychiatry · 2025 · 12 cites

Recent publications

Association of preterm birth and birth size status with neurodevelopmental and psychiatric disorders in spontaneous births.

European child & adolescent psychiatry · 2025 · 12 cites

Major themes5

Birth Weight1
Infant, Small for Gestational Age1
Mental Disorders1
Neurodevelopmental Disorders1
Premature Birth1

Leading journals1

European child & adolescent psychiatry1

Leading researchers6

Chen X1
Gissler M1
Kong L1
Lavebratt C1
Liang Y1
Nivins S1

Affiliations (unnormalised)5

Center for Molecular Medicine1
Centre for Molecular Medicine1
Finnish Institute for Health and Welfare1
Karolinska Institutet1
School of Nursing and Rehabilitation1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.

Identifiers

MeSHBirth Weight

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.